Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study

被引：45
|
作者：
Taher, Ali T. [1 ]
Karakas, Zeynep [2 ]
Cassinerio, Elena [3 ]
Siritanaratkul, Noppadol [4 ]
Kattamis, Antonis [5 ]
Maggio, Aurelio [6 ]
Rivella, Stefano [7 ]
Hollaender, Norbert [8 ]
Mahuzier, Bruyere [9 ]
Gadbaw, Brian [10 ]
Aydinok, Yesim [11 ]
机构：
[1] Amer Univ, Beirut Med Ctr, Dept Internal Med, Cairo St,Riad El Solh 1107 2020,POB 11-0236, Beirut, Lebanon
[2] Istanbul Univ, Istanbul Med Fac, Dept Pediat Hematol & Oncol, Istanbul, Turkey
[3] Univ Milan, Ca Granda Fdn, Ist Ricovero & Cura Carattere Sci, Milan, Italy
[4] Mahidol Univ, Siriraj Hosp, Dept Med, Bangkok, Thailand
[5] Univ Athens, Dept Pediat 1, Athens, Greece
[6] Osped Riuniti Villa Sofia V Cervello, Franco & Piera Cutino Azienda Osped, Campus Haematol, Palermo, Italy
[7] Childrens Hosp Philadelphia, Dept Pediat, Div Hematol, Philadelphia, PA 19104 USA
[8] Novartis Pharma AG, Basel, Switzerland
[9] Novartis Pharma SAS, Rueil Malmaison, France
[10] Novartis Pharmaceut, E Hanover, NJ USA
[11] Ege Univ Hosp, Dept Pediat Hematol & Oncol, Izmir, Turkey
来源：
BLOOD | 2018年 / 131卷 / 02期
关键词：
BETA-THALASSEMIA; INEFFECTIVE ERYTHROPOIESIS; THERAPY;
D O I：
10.1182/blood-2017-06-790121
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：263 / 265
页数：3
相关论文
共 50 条
  • [1] Efficacy and Safety of Ruxolitinib in Regularly Transfused Patients with Thalassemia: Results from Single-Arm, Multicenter, Phase 2a Truth Study
    Aydinok, Yesim
    Karakas, Zeynep
    Cassinerio, Elena
    Siritanaratkul, Noppadol
    Kattamis, Antonis
    Maggio, Aurelio
    Hollaender, Norbert
    Mahuzier, Bruyere
    Gadbaw, Brian
    Taher, Ali T.
    BLOOD, 2016, 128 (22)
  • [2] Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study
    Yacoub, Abdulraheem
    Borate, Uma
    Rampal, Raajit K.
    Ali, Haris
    Wang, Eunice
    Gerds, Aaron T.
    Hobbs, Gabriela S.
    Kremyanskaya, Marina
    Winton, Elliott
    O'Connell, Casey
    Goel, Swati
    Oh, Stephen T.
    Schiller, Gary J.
    Assad, Albert
    Erickson-Viitanen, Sue
    Zhou, Feng
    Daver, Naval
    BLOOD, 2022, 140
  • [3] Iron Chelation in Regularly Transfused Patients with Aplastic Anemia: Efficacy and Safety Results from the Large Deferasirox EPIC Trial
    Lee, Jong Wook
    Yoon, Sung-Soo
    Shen, Zhi Xiang
    Hsu, Hui-Chi
    Ganser, Arnold
    Habr, Dany
    Domokos, Gabor
    Hmissi, Abdel
    Porter, John B.
    BLOOD, 2008, 112 (11) : 167 - 168
  • [4] Long-Term Efficacy and Safety Results From a Phase II Study of Ruxolitinib in Patients with Polycythemia Vera
    Verstovsek, Srdan
    Passamonti, Francesco
    Rambaldi, Alessandro
    Barosi, Giovanni
    Rosen, Peter J.
    He, Shui
    Contel, Nancy
    Mookerjee, Bijoyesh
    Rumi, Elisa
    Gattoni, Elisabetta
    Pieri, Lisa
    Cazzola, Mario
    Kantarjian, Hagop M.
    Barbui, Tiziano
    Vannucchi, Alessandro M.
    BLOOD, 2012, 120 (21)
  • [5] Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: Initial Results of a Phase II Study
    Rampal, Raajit K.
    Verstovsek, Srdan
    Devlin, Sean M.
    Stein, Eytan M.
    Kadia, Tapan M.
    Mauro, Michael J.
    Pemmaraju, Naveen
    Alvarez, Kelsey
    Ard, Nicole
    Goodman, Tawni
    Marek, Kelly
    Bose, Prithviraj
    BLOOD, 2018, 132
  • [6] Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients With Myelofibrosis: Initial Results of a Phase II Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (01) : 8 - 10
  • [7] Efficacy and Safety of Fedratinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Results from the Phase 3 Randomized FREEDOM2 Study
    Harrison, Claire N.
    Mesa, Ruben
    Talpaz, Moshe
    Al-Ali, Haifa Kathrin
    Xicoy, Blanca
    Passamonti, Francesco
    Palandri, Francesca
    Benevolo, Giulia
    Vannucchi, Alessandro M.
    Mediavilla, Clemence
    Iurlo, Alessandra
    Kim, InHo
    Brown, Patrick
    Hernandez, Christopher
    Rose, Shelonitda
    Wang, Jia
    Kiladjian, Jean-Jacques
    BLOOD, 2023, 142
  • [8] Efficacy and Safety of Once-Daily, Oral Iron Chelator Deferasirox (Exjade®) in a Large Group of Regularly Transfused Patients with β-Thalassemia Major
    Cappellin, Maria Domenica
    Elalfy, Mohsen Saleh
    Kattamis, Antonis
    Seymour, John F.
    Lee, Chan Lee
    Porter, John B.
    El-Beshlawy, Amal
    Habr, Dany
    Domokos, Gabor
    Hmissi, Abdel
    Taber, Ali
    BLOOD, 2008, 112 (11) : 1321 - 1321
  • [9] Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study
    Rampal, Raajit K.
    Verstovsek, Srdan
    Devlin, Sean M.
    King, Amber C.
    Stein, Eytan M.
    Pemmaraju, Naveen
    Mauro, Michael J.
    Kadia, Tapan M.
    Montalban-Bravo, Guillermo
    Alvarez, Kelsey
    Ard, Nicole
    Goodman, Tawni
    Taylor, Bria
    Bose, Prithviraj
    BLOOD, 2019, 134
  • [10] Safety and efficacy of pegylated interferon α-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia
    Harmatz, Paul
    Jonas, Maureen M.
    Kwiatkowski, Janet L.
    Wright, Elizabeth C.
    Fischer, Roland
    Vichinsky, Elliott
    Giardina, Patricia J.
    Neufeld, Ellis J.
    Porter, John
    Olivieril, Nancy
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 (08): : 1247 - 1251
12345